M&A / Deals Novartis to acquire Myricx Bio in up to $1.5bn deal Pharmaceutical Business ReviewThe deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments.OncologyRead full story pharminent July 6, 2026 (Last updated: July 6, 2026) Pharmaceutical Business Review The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UK, pharma industry pilot rapid access routes for medicinesNext: Novartis Acquires UK ADC Specialist Myricx Bio for Up to $1.5 Billion Related Stories M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma pharminent July 2, 2026 M&A / Deals Insilico Medicine, Takeda partner on AI-driven drug discovery pharminent July 2, 2026 M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal pharminent July 1, 2026
